Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN7 | P35236 | 5/20 | 0.42 |
| ▸ | DUSP3 | P51452 | 5/20 | 0.42 |
| ▸ | AR | P10275 | 2/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | PTPRC | P08575 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | VNN1 | O95497 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 2/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29492591 | 1.00 | PTPN7 (0.42) | PTPN7DUSP3ARRXRARXRB | |
| SCHEMBL624789 | 0.85 | KIF11 (0.49) | RXRARXRBRXRGPTPRCPTPN1 | |
| SCHEMBL8882398 | 0.85 | RXRA (0.43) | ARRXRARXRBRXRGPTPRC | |
| SCHEMBL6211745 | 0.83 | AR (0.46) | PTPN7DUSP3ARVNN1NR3C2 | |
| SCHEMBL4713741 | 0.82 | MEN1 (0.48) | PTPN7DUSP3ARVNN1CTSS | |
| SCHEMBL24108411 | 0.80 | AR (0.53) | ARRXRARXRBRXRG | |
| SCHEMBL1678953 | 0.80 | IDO1 (0.56) | ARRXRARXRBRXRGPTPRC | |
| SCHEMBL4712811 | 0.80 | RXRA (0.40) | ARRXRARXRBRXRGPTPRC | |
| SCHEMBL20214380 | 0.80 | CTSS (0.41) | ARRXRARXRBRXRGPTPRC | |
| SCHEMBL12332127 | 0.80 | PTPRC (0.48) | RXRARXRBRXRGPTPRCPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240034717-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA A/S (DK) | 2024-02-01 | — | — | US | disclosed |
| US-20230247900-A1 | Organic Compound of Formula (I) for Use in Organic Electronic Devices, an Organic Electronic Device Comprising a Compound of Formula (I) and a Display Device Comprising the Organic Electronic Device | NOVALED GMBH (DE) | 2023-08-03 | — | — | US | disclosed |
| US-20230247900-A1 | Organic Compound of Formula (I) for Use in Organic Electronic Devices, an Organic Electronic Device Comprising a Compound of Formula (I) and a Display Device Comprising the Organic Electronic Device | NOVALED GMBH (DE) | 2023-08-03 | — | — | US | disclosed |
| EP-4217065-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | Saniona A/S (DK) | 2023-08-02 | — | — | EP | disclosed |
| US-20230225201-A1 | Organic Light Emitting Diode and Device Comprising the Same | NOVALED GMBH (DE) | 2023-07-13 | — | — | US | disclosed |
| US-20230225201-A1 | Organic Light Emitting Diode and Device Comprising the Same | NOVALED GMBH (DE) | 2023-07-13 | — | — | US | disclosed |
| CN-116368112-A | Novel potassium channel inhibitors | 萨尼奥纳有限责任公司 | 2023-06-30 | — | — | CN | disclosed |
| WO-2022263531-A1 | ACTIVE-MATRIX OLED DISPLAY | NOVALED GMBH (DE) | 2022-12-22 | — | — | WO | disclosed |
| EP-4106027-A1 | ACTIVE-MATRIX OLED DISPLAY | Novaled GmbH (DE) | 2022-12-21 | — | — | EP | disclosed |
| EP-3989303-A1 | ORGANIC COMPOUND OF FORMULA (I) FOR USE IN ORGANIC ELECTRONIC DEVICES, AN ORGANIC ELECTRONIC DEVICE COMPRISING A COMPOUND OF FORMULA (I) AND A DISPLAY DEVICE COMPRISING THE ORGANIC ELECTRONIC DEVICE | Novaled GmbH (DE) | 2022-04-27 | — | — | EP | disclosed |
| US-20070185154-A1 | 1H-pyrrolo[2,3-c]pyridine-7-carboxylic acid (4-tert-butyl-benzyl)-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-amide; cardiovascular diseases such as atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemi | HOFFMANN-LA ROCHE INC. | 2007-08-09 | — | — | US | disclosed |
| CN-1993323-A | Indole, indazole or indoline derivatives | HOFFMANN LA ROCHE (CH) | 2007-07-04 | — | — | CN | disclosed |
| EP-1776338-A1 | INDOLE, INDAZOLE OR INDOLINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-04-25 | — | — | EP | disclosed |
| US-20060030613-A1 | Indole, indazole and indoline derivatives as CETP inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | US | disclosed |
| WO-2006013048-A1 | INDOLE, INDAZOLE OR INDOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | WO | disclosed |
| US-6673923-B2 | PYRAZOLE AND PYRAZOLONE DERIVATIVES, USEFUL AS RNA POLYMERASE INHIBITORS AND ANTIBIOTICS | TULARIK INC. | 2004-01-06 | — | — | US | disclosed |
| US-6528657-B2 | For use in electroluminescence light emission element and can emit lights of various colors when an energy such as electric energy or electromagnetic energy is applied thereto | TAIHO INDUSTRIES CO., LTD. (JP) | 2003-03-04 | — | — | US | disclosed |
| US-20030023099-A1 | Novel fluorescent carbazole derivative | HIROSE ENGINEERING CO., LTD. (JP) | 2003-01-30 | — | — | US | disclosed |
| US-20020049205-A1 | Pyrazole antimicrobial agents | AMGEN INC. | 2002-04-25 | — | — | US | disclosed |
| WO-2001082930-A1 | PYRAZOLE ANTIMICROBIAL AGENTS | TULARIK INC. (US) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030613-A1 | Indole, indazole and indoline derivatives as CETP inhibitors | CETP, NAT1, MTTP | PTPN7 3868/4885DUSP3 2760/4885AR 1432/4885 |
| US-20020049205-A1 | Pyrazole antimicrobial agents | POLRMT, POLR1C, RNGTT | PTPN7 4027/4885DUSP3 832/4885AR 4066/4885 |
| US-20070185154-A1 | 1H-pyrrolo[2,3-c]pyridine-7-carboxylic acid (4-tert-butyl-benzyl)-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-amide; cardiovascular diseases such as atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemi | APOB, CETP, LIPC | PTPN7 429/4885DUSP3 4554/4885AR 4544/4885 |
| US-20240034717-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNN2, KCNJ2, KCNN1 | PTPN7 3347/4885DUSP3 1758/4885AR 4214/4885 |
| US-20230247900-A1 | Organic Compound of Formula (I) for Use in Organic Electronic Devices, an Organic Electronic Device Comprising a Compound of Formula (I) and a Display Device Comprising the Organic Electronic Device | AOX1, CYP2C19, CYP2C9 | PTPN7 1503/4885DUSP3 4376/4885AR 2771/4885 |
| US-20030023099-A1 | Novel fluorescent carbazole derivative | CBR3, AANAT, SIRT3 | PTPN7 4518/4885DUSP3 3843/4885AR 2740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.